Evaluación de la Calidad de Vida en Pacientes con Linfoma no Hodgkin y Cáncer Colo-Rectal en Diferentes Etapas Clínicas Atendidos en el Instituto Mexicano del Seguro Social

Jul 1, 2011, 00:00
10.1016/j.jval.2011.05.031
https://www.valueinhealthjournal.com/article/S1098-3015(11)01447-1/fulltext
Title : Evaluación de la Calidad de Vida en Pacientes con Linfoma no Hodgkin y Cáncer Colo-Rectal en Diferentes Etapas Clínicas Atendidos en el Instituto Mexicano del Seguro Social
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01447-1&doi=10.1016/j.jval.2011.05.031
First page : S130
Section Title : Health Outcomes Analysis
Open access? : No
Section Order : 8

Introduction

In Mexico during 2008, were reported 127,604 new cancer cases, 6,347 of them were colorectal cancer cases and 4,276 Non-Hodgkin Lymphoma (NHL) cases.

Objective

To Evaluate Health Related Quality of Life in Non-Hodgkin Lymphoma and colorectal cancer cases in different clinical stages, attended in a High Specialty Medical facility at the Instituto Mexicano del Seguro Social, during a 13 month period.

Results

162 patients were included, 56.8% (n=92) with NHL and 43.2% (n=70) with colorectal cancer. The scores obtained in the NHL group were: Global health status/QoL: 67.75 (±27.55), physical functioning 69.64 (±29.98), role functioning 71.38 (±33.73), emotional functioning 69.7 (±26.57), cognitive functioning 75.36 (±28.01), social functioning 79.35 (±29.38), fatigue 35.27 (±28.27), nausea and vomiting 13.41 (±21.85), pain 28.08 (±30.25), dyspnea 19.20 (±32.11), insomnia 30.80 (±38.03), appetite lost 26.45 (±36.16), constipation 19.20 (±32.11), diarrhea 12.32 (±26.48), financial difficulties 26.09 (±35.57). In colorectal cancer patients the scores were: Global health status/QoL: 68.21 (±24.46), physical functioning 67.38 (±30.45), role functioning 65.48 (±35.70), emotional functioning 66.43 (±26.84), cognitive functioning 78.57 (±26.49), social functioning 75.24 (±31.05), fatigue 37.78 (±31.62), nausea and vomiting 20.00 (±28.32), pain 37.38 (±34.45), dyspnea 11.90 (±26.64), insomnia 28.09 (±35.73), appetite lost 23.81 (±36.40), constipation 19.05 (±32.88), diarrhea 20.95 (±31.17), financial difficulties 34.76 (±38.67).

Conclusions

With these basal results is important a follow-up with special attention to the treatment and attendance processes, in patients with this neoplasms and their impact on the quality of life.

Categories :
  • Clinical Outcomes
  • Clinical Outcomes Assessment
  • Oncology
  • Patient-Centered Research
  • Patient-reported Outcomes & Quality of Life Outcomes
  • Specific Diseases & Conditions
Tags :
  • colo-rectal cancer
  • lymphoma
  • non-Hodgkin QLQ-C30
  • process of attendance
  • quality of life
Regions :
  • Latin America
ViH Article Tags :